Considering that the publication in the February 2022 compounding danger inform, FDA is becoming mindful of rising general public fascination in using sublingual and oral dosage forms of compounded ketamine for the therapy of psychiatric disorders. FDA understands that the chance to attain these products and solutions via telemedicine platforms https://ketalinic.com/our-products/